METTL3 and neoplasm: In melanoma, knockdown of METTL3 in bone marrow cells results in the lack of m6A modification on SPRED2, which in turn disrupts YTHDF1-mediated mRNA translation, leading to enhanced activation of NF-κB and STAT3 via the ERK pathway, contributing to tumor progression [67].